



Health Update

IMPROVED SUPPLY AND ACCESSIBILITY OF OUTPATIENT COVID-19 THERAPEUTICS

May 17, 2022

The following information is issued on behalf of the SF COVID Task Force

Three FDA-authorized oral medications for outpatient treatment of mild to moderate symptomatic COVID-19 in people who are at higher risk for severe disease -- Nirmatrelvir/ Ritonavir (Paxlovid), Molnupravir (Lagevrio) and Bebtelovimab -- **are no longer in short supply and should be used whenever clinically appropriate.**

Sotrovimab is no longer authorized while the Omicron variant is prevalent, due to decreased efficacy.

In addition, access to COVID-19 therapeutics continues to improve due to wider pharmacy availability and locations that encompass testing and treatment (Test-to-Treat). Test-to-Treat sites can be found here: <https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com>

More information about outpatient COVID-19 therapeutics, who is eligible, and how to prescribe them can be found here: <https://www.sfdph.org/dph/files/ig/COVID-Therapeutics-Guidance-for-Providers.pdf>

Information to Guide Providers' Prescriptions of COVID-19 Therapies

The National Institutes of Health (NIH) has created a framework to allocate these medicines to those who will have the greatest benefit when supply is limited. At the time of this health alert, due to increased availability, patients meeting any of the criteria below are eligible.

Who is currently eligible for outpatient COVID-19 Therapies?

1. Recently diagnosed with symptomatic COVID-19, AND
2. Mild or moderate disease NOT requiring hospitalization, AND
3. At risk for progression to severe COVID-19 due to one of the following:
 - Age 65 and older
 - Age 12 and up and immunocompromised



- Age 12 and up with risk factors for severe disease including heart, lung, vascular or neurologic conditions, being overweight or having substance use or mental health comorbidities. Other eligible health conditions can be found here: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>
- Unvaccinated, incompletely vaccinated
- Pregnant

More information on mechanism, dosing, contraindications and other clinical considerations of these therapies can be found here: <https://www.sfdph.org/dph/files/ig/COVID-Therapeutics-Guidance-for-Providers.pdf>

Pharmacies that stock COVID-19 Therapies:

Prescriptions can now be sent to *any* Walgreens, CVS, and Safeway. To reduce barriers to medication access, the pharmacies plan to ensure that all stores either stock the products or are able to order them to any of their locations. Walgreens offers free delivery upon request on prescription. See our guidance for providers here: <https://www.sfdph.org/dph/files/ig/COVID-Therapeutics-Guidance-for-Providers.pdf>

Where Patients can access COVID-19 Therapies

Patients may also be able to access COVID-19 therapeutics through their Medi-Cal insurance plan, within their individual health system or at Test-To-Treat centers. To access a full list of sites where COVID-19 therapies are available to patients, see <https://sf.gov/get-treated-covid-19>

Additional Resources

- NIH Guidance: “The COVID-19 Treatment Guidelines Panel's Statement on Therapies for High-Risk, Non-hospitalized Patients with Mild to Moderate COVID-19.”
<https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/>
- NIH Guidance: “The COVID-19 Treatment Guidelines Panel's Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints”
<https://www.covid19treatmentguidelines.nih.gov/overview/prioritization-of-therapeutics/>

To view or sign up for SFDPH health advisories and alerts, visit www.sfdcp.org/health-alerts-emergencies/health-alerts/.